

72. The polypeptide according to claim 70, wherein said polypeptide further comprises Met at the amino terminus.

73. The polypeptide according to Claim 70, wherein said polypeptide further comprises amino acids 1-31 of Figure 7 at the amino terminus.

74. The polypeptide according to Claim 51, wherein said polypeptide consists of amino acids 32-194 of Figure 7.

75. The polypeptide according to Claim 74, wherein said polypeptide is unglycosylated.

76. The polypeptide according to Claim 74, wherein the polypeptide is glycosylated.

77. A pharmaceutical composition comprising the polypeptide according to Claim 74 and a pharmaceutically acceptable carrier.--

REMARKS

Claims 13-14, 23-24, 29, 36-37, 39, 40-43 are pending in this application. Applicants herewith cancel claims 13-14, 23-24, 29, 36-37, 39, 40-43, without prejudice or disclaimer and add new claims 44-77. Thus, with the entry of this amendment, claims 44-77 will be active in this case.


The amendment to the specification is to reinstate the original language in the application that was removed by way of the Preliminary Amendment dated March 31, 1989. Thus, no new matter has been added with this amendment.

CONCLUSION

Applicants believe the above claims are allowable and look forward to discussing the same at an interview to be arranged according to mutual convenience.

November 20, 1998
Date

Respectfully submitted,



Patricia D. Granados
Reg. No. 33,683

FOLEY & LARDNER
3000 K STREET, N.W.
SUITE 500
WASHINGTON, DC 20007
202-672-5477